Resumo

DOMINGUEZ-MORENO, Rogelio; VEGA-BOADA, Felipe  e  MENA-ARCEO, Roger Gaspar. New treatments against migraine. Med. interna Méx. [online]. 2019, vol.35, n.3, pp.397-405.  Epub 05-Mar-2021. ISSN 0186-4866.  https://doi.org/10.24245/mim.v35i3.2712.

Migraine is a disease with high prevalence and disability that affects the economically active population, so it represents a public health problem. Nowadays, the vast majority of patients who are candidates for preventive treatment do not receive it, either due to lack of knowledge of the physician or because of the complexity and/or adverse effects of the available treatments. There are new drugs that act in the calcitonin generelated peptide pathway (gepants and monoclonal antibodies) and in the selective agonism of the serotonin 1F receptor, which have shown clinical effectiveness with few adverse effects. Its efficacy, however, may not be greater than that of the drugs already known. At the moment three monoclonal antibodies have been approved (erenumab, galcanezumab and fremanezumab) and there are studies of phase III of other pharmacological groups. Therefore, it is important to update the knowledge associated with these new therapeutic focuses and the mechanism of action of these new treatments that will be available soon.

Palavras-chave : Migraine; Monoclonal antibodies.